Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Stevanato Group ( (STVN) ) has provided an update.
In the first quarter of 2026, Stevanato Group reported revenue of €273.6 million, up 7% year-over-year, or 10% at constant currency, with high-value solutions rising 17% and reaching 47% of total sales. The Biopharmaceutical and Diagnostic Solutions segment grew 13% to €249.0 million, offsetting a 31% revenue decline in the Engineering segment, while adjusted EBITDA margin improved 150 basis points to 23.9% and diluted EPS came in at €0.10, or €0.11 on an adjusted basis.
Operating profitability strengthened as gross margin improved to 27.5% and operating margin to 14.2%, supported by scaling new facilities in Fishers, Indiana, and Latina, Italy, and optimization efforts in Denmark, despite higher depreciation and FX headwinds. The company generated €5.5 million of free cash flow, ended March 31, 2026 with €111.7 million in cash and €337.7 million in net debt, and maintained its full-year 2026 guidance, signaling confidence in continued growth driven by biologics and GLP-1 demand and its strategic emphasis on high-value, scalable solutions.
The most recent analyst rating on (STVN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Stevanato Group stock, see the STVN Stock Forecast page.
Spark’s Take on STVN Stock
According to Spark, TipRanks’ AI Analyst, STVN is a Neutral.
The score is anchored by solid financial stability but tempered by weaker cash flow consistency. A positive earnings-call outlook and guidance support the outlook, while bearish technicals and a relatively high P/E weigh on near-term attractiveness.
To see Spark’s full report on STVN stock, click here.
More about Stevanato Group
Stevanato Group S.p.A., listed on the NYSE under ticker STVN, is a leading global provider of drug containment, drug delivery, and diagnostic solutions serving pharmaceutical, biotechnology, and life sciences customers. The Italy-based company focuses on high-value products such as high-performance syringes, EZ-fill vials, and other containment and delivery systems, with growing exposure to biologics and injectable therapies, including GLP-1 treatments.
Average Trading Volume: 611,999
Technical Sentiment Signal: Hold
Current Market Cap: $5.19B
For a thorough assessment of STVN stock, go to TipRanks’ Stock Analysis page.